The DCAF1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human Raji B lymphocytes. This product provides a loss-of-function model for the DCAF1 gene (also known as VprBP), encoding a substrate receptor for the CUL4-DDB1 E3 ubiquitin ligase complex. The polyclonal format ensures a heterogeneous knockout population, reflecting diverse editing outcomes while maintaining robust target-gene disruption across the cell pool. These cells serve as a valuable tool for dissecting DCAF1-dependent cellular processes without the confounding effects of clonal selection.
The Raji host cell line originates from a Burkitt lymphoma patient and represents a well-characterized model of B lymphocytes. These cells are widely used to study B-cell biology, including immune responses, antibody production, and antigen presentation. Raji cells are particularly relevant for investigating mechanisms of B-cell lymphomagenesis and host?Cvirus interactions, notably with Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV). The inherent proliferative capacity and well-defined signaling networks of Raji cells make them an ideal chassis for examining the functional consequences of DCAF1 loss.
Mechanistically, DCAF1 (DDB1- and CUL4-associated factor 1) functions as the substrate recognition subunit of the CRL4 (Cullin-RING ligase 4) E3 ubiquitin ligase complex. It directly interacts with DDB1, CUL4A/B, and RBX1 to recruit substrates such as p53 and histone H2A for ubiquitination and subsequent proteasomal degradation or signaling. DCAF1 activity is regulated by upstream signals including DNA damage, HIV-1 Vpr, CDK inhibitors, and p53. Downstream, its ubiquitination targets influence p21 stability, miRNA biogenesis machinery, and chromatin remodeling. The COP9 signalosome modulates CRL4 activity through deneddylation. Disruption of DCAF1 abrogates key ubiquitination events, perturbing cell cycle progression, DNA damage repair, and microRNA processing.
Within the Raji B-cell context, DCAF1 knockout holds particular significance for understanding B-cell lymphoma pathology. DCAF1-mediated ubiquitination of tumor suppressors such as p53 may contribute to lymphomagenesis, and its interaction with HIV-1 Vpr implicates CRL4 in viral pathogenesis. Loss of DCAF1 function is predicted to sensitize cells to DNA-damaging agents and modulate cell cycle checkpoints, providing insights into therapeutic vulnerabilities. This model enables researchers to dissect how aberrant ubiquitin ligase activity drives oncogenesis and immune dysregulation in B-lymphoid cells.
Key research applications include ubiquitin ligase function, DNA damage response, cell cycle regulation, and virus?Chost interactions. Compatible assays include Western blotting, ubiquitination assays, co-immunoprecipitation, flow cytometry, cell cycle analysis, apoptosis assays, RT-qPCR, RNA-seq, phospho-signaling, and drug sensitivity studies. For additional specifications, please contact Ascent Research.
